Todd Gates, DO
Psychiatry · West Melbourne, FLNPI 1992702260
Payments from drug & device makers
Across 2,188 payments — averaging $541.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$775K
- Neurocrine Biosciences, Inc.$238K
- Axsome Therapeutics, Inc.$85K
- E.r. Squibb & Sons, L.L.C.$73K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$7K
- Vanda Pharmaceuticals Inc.$2K
- plus $6K from 16 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 1,224 | $775,350 |
| Neurocrine Biosciences, Inc. | 298 | $237,628 |
| Axsome Therapeutics, Inc. | 111 | $85,013 |
| E.r. Squibb & Sons, L.L.C. | 76 | $72,611 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 106 | $6,888 |
| Vanda Pharmaceuticals Inc. | 67 | $1,583 |
| Alkermes, Inc. | 59 | $1,518 |
| Otsuka America Pharmaceutical, Inc. | 58 | $957 |
| Johnson & Johnson | 37 | $715 |
| Sunovion Pharmaceuticals Inc. | 47 | $633 |
| Teva Pharmaceuticals USA, Inc. | 29 | $632 |
| Lundbeck LLC | 14 | $367 |
| Indivior Inc. | 16 | $331 |
| Biohaven Pharmaceuticals, Inc. | 12 | $315 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $233 |
| Noven Therapeutics, LLC | 12 | $198 |
| Corium, LLC | 1 | $110 |
| Luye Pharma (USA) Ltd. | 3 | $82 |
| Noven Pharmaceuticals, Inc. | 1 | $27 |
| Bausch Health US, LLC | 1 | $21 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$1,185,244 in reported general payments places this provider in the 95th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other psychiatry in West Melbourne
- Edwin GomezWeston$24.9M
- Rishi KakarTamarac$23.9M
- Peter VentreOakland Park$18.7M
- Jose GamezHialeah$14.8M
- John JoyceJacksonville$13.6M
- Silvia Silva-DulucMiami$11.7M
- Kelley WilsonTampa$11.1M
- Emilio Mantero-AtienzaMiami Beach$10.9M
- Patricia JunqueraMiami$10.8M
- Olga LapeyraLauderhill$10M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.